Stocks
DermTech, Inc.DMTK
NASDAQHealthcareBiotechnology$0.09-11.32%
Specializing in non-invasive genomics tests for skin cancer detection, this company develops diagnostic tools that reduce the need for surgical biopsies. Its flagship product, the Pigmented Lesion Assay, targets early melanoma detection, a key focus area for healthcare cost reduction. Investors monitor DermTech for its potential to disrupt traditional dermatologic diagnostics despite its micro-cap status.
Market Cap: $3.3M52W Range: $0.04 – $3.90
Congressional Interest in DermTech, Inc. (DMTK)
1 member of Congress has disclosed 3 trades in DermTech, Inc. (DMTK), a Healthcare company. The buy/sell breakdown shows 2 purchases versus 1 sale, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
3
Unique Politicians
1
Buys
2
Sells
1
Who in Congress Is Trading DMTK?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2021-01-27 | Tom Malinowski | sell | $1K – $15K |
| 2021-01-11 | Tom Malinowski | buy | $1K – $15K |